Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100044/S058

Propel Contour Sinus Implant

Intersect Ent. · Decision date Nov 7, 2025

FDA DECISIONP100044/S058

What did the FDA approve?

FDA records P100044/S058 as a supplement to PMA P100044, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 7, 2025.

FDA approval order statement

to designate pre-deployment dimensional specifications as reference values for the Propel Contour Sinus Implant
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Ear, Nose, Throat
Decision date
Nov 7, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P100044/S058
Regulatory pathway
PMA supplement
Product code
OWO
Decision code
APPR
Decision date
Nov 7, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Drug-eluting sinus stent.

Product code
OWO
FDA device class
3

For the original device and its historical approval scope, see PMA P100044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100044/S058 received

    Application receipt date recorded by FDA.

  2. P100044/S058 · FDA decision

    Real-Time Process

  3. P100044/S059 · Related supplement

    Propel, Propel Mini (including Propel Mini with Straight Delivery System), and Propel Contour Sinus Implants

Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100044

Product / regulatory recordCompanyPathwayDecision dateSource
PROPELP100044
Intersect Ent.PMA approvalAug 11, 2011FDA
Intersect Ent.PMA supplementJul 31, 2026FDA
PROPELP100044/S061
Intersect Ent.PMA supplementSep 22, 2026FDA
Intersect Ent.PMA supplementSep 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Intersect Ent.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1555 Adams Dr., Menlo Park, CA, 94025

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records